New Insights into Alzheimer’s Treatment Potential
Recent research has uncovered a previously unrecognized “sugar code” within the brain that might lead to enhanced treatments for neurological diseases, particularly Alzheimer’s. A study featured in the Nature Metabolic Journal indicates that breaking down glycogen, which is a stored form of glucose, could help diminish the toxic protein buildup linked to common forms of dementia.
This research stands out as one of the initial investigations demonstrating that glycogen might have a beneficial role in brain health, shared lead author Dr. Pankaji Kapahi from the California Institute for Aging.
Key Findings
The investigation started with genetically altered fruit flies designed to replicate taupathy, where the tau protein accumulates, akin to conditions seen in Alzheimer’s. Notably, these modified flies displayed less severe brain damage and shorter lifespans.
To translate these findings to human applications, researchers also examined neurons derived from human patient cells with tau mutations typical in Alzheimer’s and related conditions. They observed increased glycogen levels in both fly and human models, alongside impaired glycogen degradation—an unexpected result since glycogen was previously believed to primarily exist in muscles and the liver.
Interestingly, the excess glycogen appeared to exacerbate the disease process. The tau protein interacted with glycogen, hindering its breakdown, which in turn compromised the nerves’ ability to shield against cell damage. However, by enhancing an enzyme called glycogen phosphorylase (GLYP), which facilitates glycogen degradation, the researchers found they could reduce damage in both flies and human nerves.
The study also delved into whether modifying dietary habits, specifically reducing protein intake, could bolster brain health in flies. Remarkably, a lower protein diet led to longer lifespans and improved cognitive function in these insects.
Dr. Kapahi noted that this improvement seemed correlated with a failure of glycogen breakdown, leading to critical discoveries about how glycogen metabolism influences brain health concerning tau accumulation.
Alongside this, scientists have developed a drug using a molecule named 8-BR-CAMP, simulating the effects of dietary restriction. They aren’t advising a low-protein diet just yet but hint that their findings might open doors to nutritional or pharmacological strategies aimed at slowing Alzheimer’s progression.
Research Limitations
Despite these promising results, researchers recognize several limitations. For instance, the study has so far focused only on fruit fly and cell models, without testing in living humans. There remains uncertainty about whether targeting glycogen degradation will be effective or safe in human patients.
Dr. Michael Okun, a neurologist and medical advisor to the Parkinson’s Foundation, emphasized the study’s significance. He highlighted how broken glycogen, rather than feeding energy production, might divert to antioxidant pathways, potentially aiding in neuronal protection against oxidative stress.
As Alzheimer’s affects over 7 million individuals in the U.S., ongoing research is crucial. While there’s no cure currently, some existing medications can temporarily slow the disease’s advancement and enhance patients’ quality of life.
